Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
98.73
-3.51 (-3.43%)
Aug 20, 2026, 11:42 AM EDT - Market open
Mirum Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 618.07 | 521.31 | 336.89 | 186.37 | 77.06 | 19.14 |
Revenue Growth | 44.02% | 54.74% | 80.76% | 141.85% | 302.67% | - |
Gross Profit Gross Profit Growth | 505.11 | 421.07 | 255.25 | 139.34 | 64.69 | 17.24 |
Operating Income Operating Income Growth | -96.23 | -22.14 | -87.61 | -109.15 | -131.22 | -173.41 |
Net Income Net Income Growth | -860.21 | -23.36 | -87.94 | -163.42 | -135.67 | -83.99 |
Earnings Per Share EPS Growth | -15.34 | -0.47 | -1.85 | -4.00 | -4.02 | -2.77 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Livmarli Livmarli Growth | 441.15 | 360.01 | 213.3 | 141.8 | 75.06 | 3.14 |
Bile Acid Medicines Bile Acid Medicines Growth | 176.92 | 161.31 | 123.11 | 37.08 | - | - |
License and Other License and Other Growth | - | - | 0.48 | 7.5 | 2 | 16 |
Revenue (Total) Revenue (Total) Growth | 618.07 | 521.31 | 336.89 | 186.37 | 77.06 | 19.14 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 438.29 | 383.33 | 280.32 | 286.33 | 151.72 | 156.54 |
Total Debt Total Debt Growth | 762.95 | 319.45 | 317.76 | 308.14 | 2.19 | 2.61 |
Net Cash (Debt) Net Cash Growth | -324.66 | 63.88 | -37.45 | -21.82 | 149.53 | 153.93 |
Net Cash Growth | - | - | - | - | -2.86% | -32.65% |
Net Cash Per Share Net Cash Per Share Growth | -5.79 | 1.27 | -0.79 | -0.53 | 4.40 | 5.08 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -227.27 | 55.83 | 10.33 | -70.94 | -120.14 | -132.76 |
Capital Expenditures CapEx Growth | -1.47 | -0.95 | -0.99 | -0.11 | -0.28 | -0.02 |
Free Cash Flow Free Cash Flow Growth | -228.74 | 54.87 | 9.33 | -71.05 | -120.41 | -132.78 |
Free Cash Flow Growth | - | 488.01% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 81.73% | 80.77% | 75.77% | 74.76% | 83.94% | 90.06% |
Operating Margin | -15.57% | -4.25% | -26.00% | -58.57% | -170.28% | -906.12% |
Pretax Margin | -138.75% | -4.11% | -25.80% | -87.15% | -184.36% | -438.66% |
Profit Margin | -139.18% | -4.48% | -26.10% | -87.68% | -176.05% | -438.86% |
FCF Margin | -37.01% | 10.53% | 2.77% | -38.12% | -156.26% | -693.81% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
P/FCF Ratio | - | 74.40 | 212.71 | - | - | - |
PS Ratio | 10.74 | 7.83 | 5.89 | 7.38 | 9.32 | 25.41 |